{{Rsnum
|rsid=5092
|Gene=APOA4
|Chromosome=11
|position=116822748
|Orientation=minus
|ReferenceAllele=G
|GMAF=0.2507
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=APOA4
}}[[rs5092]] is a SNP in the apolipoprotein A4 [[APOA4]] gene.

In a study of 67 mostly Caucasian patients prescribed the atypical antipsychotic [[olanzapine]], carriers of a [[rs5092]](G) allele were less likely to gain significant weight compared to [[rs5092]](A;A) carriers, as assessed by physiogenomic analysis of corresponding weight profiles. Two other SNPs, [[rs4765623]] and [[rs7412]], were also significantly associated with weight profiles in these patients.{{PMID|17199131}}

{{PMID Auto
|PMID=19592705
|Title=Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men
|OA=1
}}

{{PMID Auto
|PMID=18254975
|Title=Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat.
|OA=1
}}

{{PMID Auto
|PMID=19057464
|Title=Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}